Kura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have earned an average rating of “Moderate Buy” from the thirteen research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and ten have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $25.4615.

Several equities research analysts have commented on the stock. Lake Street Capital began coverage on shares of Kura Oncology in a research report on Tuesday, April 14th. They issued a “buy” rating and a $23.00 price target on the stock. Citigroup restated a “market outperform” rating on shares of Kura Oncology in a research report on Thursday, May 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research note on Friday, July 17th. Jefferies Financial Group set a $24.00 target price on shares of Kura Oncology in a report on Thursday, May 28th. Finally, CLSA set a $24.00 target price on shares of Kura Oncology in a research note on Thursday, June 4th.

Insider Activity

In other Kura Oncology news, insider Mollie Leoni sold 84,929 shares of the company’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $9.82, for a total value of $834,002.78. Following the transaction, the insider owned 182,345 shares of the company’s stock, valued at approximately $1,790,627.90. This represents a 31.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Kura Oncology

A number of institutional investors and hedge funds have recently modified their holdings of the stock. IFP Advisors Inc boosted its position in shares of Kura Oncology by 115.3% in the 4th quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after purchasing an additional 1,284 shares during the period. Royal Bank of Canada lifted its stake in Kura Oncology by 7.6% during the fourth quarter. Royal Bank of Canada now owns 19,577 shares of the company’s stock valued at $203,000 after buying an additional 1,375 shares in the last quarter. Allworth Financial LP lifted its stake in Kura Oncology by 59.9% during the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock valued at $43,000 after buying an additional 1,553 shares in the last quarter. Focus Partners Advisor Solutions LLC boosted its holdings in shares of Kura Oncology by 7.9% in the fourth quarter. Focus Partners Advisor Solutions LLC now owns 22,889 shares of the company’s stock worth $238,000 after buying an additional 1,682 shares during the period. Finally, ProShare Advisors LLC boosted its holdings in shares of Kura Oncology by 10.0% in the fourth quarter. ProShare Advisors LLC now owns 18,572 shares of the company’s stock worth $193,000 after buying an additional 1,692 shares during the period.

Kura Oncology Stock Down 2.3%

KURA opened at $10.15 on Tuesday. Kura Oncology has a one year low of $5.45 and a one year high of $12.49. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.14 and a current ratio of 6.15. The stock’s fifty day moving average is $10.30 and its 200-day moving average is $9.28. The company has a market capitalization of $901.02 million, a PE ratio of -3.03 and a beta of 0.35.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.05. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%.The business had revenue of $18.27 million during the quarter, compared to analyst estimates of $25.97 million. On average, equities analysts predict that Kura Oncology will post -3.45 EPS for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.